Specimen:

Bone Marrow in EDTA Tube

Collection Medium:

 
Lavender top tube (EDTA)

Minimum:

Preferred Specimen:  2.1 mL Bone Marrow in EDTA tube
Absolute Minimum:  1.0 mL Bone Marrow in EDTA tube
After collection of the sample, draw date and time must be written onto 
the tube and included as requested information.  Ship immediately. Draw 
date and time is required to perform testing. Ship sample immediately 
due to short sample stability of 72 hours. If the stability of the 
sample can not be determined, delay in result or cancellation of test 
may occur.

Rejection Criteria:

Hemolysis, Lipemia, Frozen samples, Clotted whole blood samples, 
Clotted bone marrow samples.

Delivery Instructions:

Submit specimen to laboratory as soon as possible after collection.

Specimen
Instructions:

Sample must be received within 72 hours of collection.

Testing Schedule:

Set up one day per week.

Analytic Time:

within 10 days

Reference Range:

See report.

Comments:

The plasma based molecular assay is based on the new concept that in
hematological diseases, tumor cell pour into their circulation their
DNA and RNA, these components can be detected in plasma. Imatinib
mesylate (ST1571;Gleevec) is a selective BCR-ABL kinase inhibitor,
effective in the treatment of chronic myelogenous leukemia (CML). Most
patients in chronic phase maintain durable responses; however, many in
blast crisis fail to respond, or relapse quickly. ABL kinase domain
mutations are the most commonly identified mechanism associated with
relapse. The molecular monitoring in the first few months of therapy
may play a crucial role in detecting patients at high risk of Imatinib
resistance.  This ABL kinase mutation assay may detect drug-resistant
mutations before clinical relapse and identify candidate suitable for
alternative therapy.

Test
Limitations:

Sample is only stable for 72 hours.

Methodology:

Real-Time Polymerase Chain Reaction, Nested Polymerase Chain Reaction, 
Sequencing

CPT Code:

83891, 83894, 83898(x6),83902, 83904, 83909, 83912

See also:
ABL Kinase Domain Mutation in CML, Whole Blood EDTA